jardiancehcp.com Report : Visit Site

Technical data of the jardiancehcp.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host jardiancehcp.com. Currently, hosted in United Kingdom and its service provider is Datapipe .

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache/2.2.15 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

skip to main content for us healthcare professionals -- menu home trial information cv outcomes safety dosing resources access search form search top menu pcp important safety information prescribing information patient information for patients other empagliflozin products search form search -- menu -- home trial information cv outcomes safety dosing resources access jardiance® (empagliflozin) information – primary care physicians jardiance® (empagliflozin) information – primary care physicians pcp cv death can strike adults with type 2 diabetes and established cv disease at any time 1 learn more about the deadly link between t2d and cvd cv death can strike adults with type 2 diabetes and established cv disease at any time 1 fight for their lives now more than ever powerful reduction in the risk of cv death in adults with t2d and established cvd see the breakthrough data explore the groundbreaking cv trial see which patients were studied in the jardiance cv outcome trial prescribe jardiance learn about once-daily dosing, common aes, and additional resources safety dosing resources access to jardiance learn about coverage and formulary access the 2018 american diabetes association ® standards of care recommend incorporating empagliflozin in addition to lifestyle management and metformin to help reduce the risk of cv death in patients with t2d and established cvd ae=adverse event; cv=cardiovascular; cvd=cardiovascular disease; t2d=type 2 diabetes. other treatments popup meet more of your patients’ needs with the jardiance family click below to explore other treatment options please see prescribing information , including boxed warning and medication guide. confirmation this web site is intended for us healthcare professionals only. i am a us healthcare professional i am a us cardiologist i am a healthcare professional outside the us i am not a healthcare professional this web site is intended for us healthcare professionals only. i am a us healthcare professional i am a us cardiologist i am a healthcare professional outside the us i am not a healthcare professional previous pause next the threat of cv death is looming cv=cardiovascular. reference: 1. national institute of diabetes and digestive and kidney diseases, us department of health and human services. bethesda, md: national institutes of health; 2008. the threat of cv death is looming cv=cardiovascular. reference: 1. national institute of diabetes and digestive and kidney diseases, us department of health and human services. bethesda, md: national institutes of health; 2008. see more indications and limitations of use jardiance is indicated to reduce the risk of cardiovascular (cv) death in adults with type 2 diabetes mellitus and established cv disease. jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. jardiance is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. important safety information contraindications: history of serious hypersensitivity to empagliflozin or any of the excipients in jardiance; severe renal impairment, end-stage renal disease, or dialysis. important safety information (continued) warnings and precautions hypotension: empagliflozin causes intravascular volume contraction and symptomatic hypotension may occur. before initiating jardiance, assess and correct volume status in the elderly, and in patients with renal impairment, low systolic blood pressure, or on diuretics. monitor for hypotension. ketoacidosis: ketoacidosis, a serious life-threatening condition requiring urgent hospitalization, has been identified in patients with type 1 and type 2 diabetes mellitus receiving sglt2 inhibitors, including empagliflozin. fatal cases of ketoacidosis have been reported in patients taking empagliflozin. patients who present with signs and symptoms of metabolic acidosis should be assessed for ketoacidosis, even if blood glucose levels are less than 250 mg/dl . if suspected, discontinue jardiance, evaluate, and treat promptly. before initiating jardiance, consider risk factors for ketoacidosis. patients may require monitoring and temporary discontinuation in situations known to predispose to ketoacidosis. acute kidney injury and impairment in renal function: empagliflozin causes intravascular volume contraction and can cause renal impairment. acute kidney injury requiring hospitalization and dialysis have been identified in patients taking sglt2 inhibitors, including empagliflozin; some reports involved patients younger than 65 years of age. before initiating jardiance, consider factors that may predispose patients to acute kidney injury. consider temporary discontinuation in settings of reduced oral intake or fluid losses. monitor patients for signs and symptoms of acute kidney injury. if it occurs, discontinue jardiance and treat promptly. empagliflozin increases serum creatinine and decreases egfr. patients with hypovolemia may be more susceptible to these changes. before initiating jardiance, evaluate renal function and monitor thereafter. more frequent monitoring is recommended in patients with egfr <60 ml/min/1.73 m 2 . discontinue jardiance in patients with a persistent egfr <45 ml/min/1.73 m 2 . urosepsis and pyelonephritis: serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization have been identified in patients receiving sglt2 inhibitors, including empagliflozin. treatment with sglt2 inhibitors increases the risk for urinary tract infections. evaluate for signs and symptoms of urinary tract infections and treat promptly. hypoglycemia: the use of jardiance in combination with insulin or insulin secretagogues can increase the risk of hypoglycemia. a lower dose of insulin or the insulin secretagogue may be required. genital mycotic infections: empagliflozin increases the risk for genital mycotic infections, especially in patients with prior infections. monitor and treat as appropriate. hypersensitivity reactions: discontinue jardiance, treat promptly, and monitor until signs and symptoms resolve. increased low-density lipoprotein cholesterol (ldl-c): monitor and treat as appropriate. most common adverse reactions (≥5%): urinary tract infections and female genital mycotic infections. drug interactions: coadministration with diuretics may enhance the potential for volume depletion. use in special populations pregnancy: jardiance is not recommended, especially during the second and third trimesters. lactation: jardiance is not recommended while breastfeeding. geriatric use: jardiance is expected to have diminished efficacy in elderly patients with renal impairment. renal function should be assessed more frequently in elderly patients. the incidence of volume depletion-related adverse reactions and urinary tract infections increased in patients ≥75 years treated with empagliflozin. cl-jar-100004 12.19.17 please see jardiance prescribing information , including patient information . reference: 1. national institute of diabetes and digestive and kidney diseases, us department of health and human services. bethesda, md: national institutes of health; 2008. privacy statement terms of use contact us sitemap working hard to make our medicines available to people who need them. visit site> jardiance is a registered trademark of boehringer ingelheim international gmbh & co. kg and used under license. use of this site is subject to the internet site legal notices and disclaimers and privacy statement. copyright © 2018 boehringer ingelheim pharmaceuticals, inc. all rights reserved. (03/18) pc-us-102130 (6/18) pc-us-102130 r1 ")

URL analysis for jardiancehcp.com

https://www.jardiancehcp.com/pcp-endo/site-variations/pcp
https://www.jardiancehcp.com/pcp-endo/pcp-endo/formulary-access
https://www.jardiancehcp.com/pcp-endo/pcp-endo/empa-reg-outcome-trial-results
https://www.jardiancehcp.com/pcp-endo/pcp-endo/cv-death-reduction
https://www.jardiancehcp.com/pcp-endo/pcp-endo/resources
https://www.jardiancehcp.com/pcp-endo/pcp-endo/dosing
https://www.jardiancehcp.com/pcp-endo/pcp-endo/sitemap
https://www.jardiancehcp.com/pcp-endo/pcp-endo/adverse-events-safety
https://www.jardiancehcp.com/pcp-endo/pcp-endo
https://www.jardiancehcp.com/pcp-endo/#main-content
https://www.jardiancehcp.com/pcp-endo/cardiologist

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: JARDIANCEHCP.COM
Registry Domain ID: 1878081723_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.corehub.net
Registrar URL: http://corehub.net
Updated Date: 2016-09-28T07:21:12Z
Creation Date: 2014-09-29T10:36:34Z
Registry Expiry Date: 2018-09-29T10:36:34Z
Registrar: Corehub, S.R.L.
Registrar IANA ID: 15
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +34935275235
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS2.OBSERVATOIREDESMARQUES.FR
Name Server: NS3.NAMESHIELD.NET
Name Server: OBS.NS1.FR
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-06-12T14:59:46Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Corehub, S.R.L.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =jardiancehcp.com

  PORT 43

  TYPE domain

DOMAIN

  NAME jardiancehcp.com

  CHANGED 2016-09-28

  CREATED 2014-09-29

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

NSERVER

  NS2.OBSERVATOIREDESMARQUES.FR 80.74.69.8

  NS3.NAMESHIELD.NET 45.63.17.113

  OBS.NS1.FR 81.92.84.146

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .